Eupraxia Pharmaceuticals Inc.
Toronto Stock Exchange EPRX.TO
Eupraxia Pharmaceuticals Inc. Capital Expenditure for the year ending December 31, 2023: USD -55.36 K
-
Eupraxia Pharmaceuticals Inc. Capital Expenditure for the year ending December 31, 2022 was USD -227.48 K, a 33.34% change year over year.
-
Eupraxia Pharmaceuticals Inc. Capital Expenditure for the year ending December 31, 2021 was USD -341.28 K.
-
Eupraxia Pharmaceuticals Inc. Capital Expenditure for the year ending December 31, 2019 was USD -7.29 K, a 92.98% change year over year.
| Date | Capital Expenditure | Free Cash Flow | Depreciation And Amortization | Deferred Income Tax |
|---|
Don’t Miss A Beat
| CEO | Dr. James A. Helliwell FRCPC, M.D. |
| IPO Date | March 9, 2021 |
| Location | Canada |
| Headquarters | 2067 Cadboro Bay Road |
| Employees | 29 |
| Sector | Healthcare |
| Industries | |
Eupraxia Pharmaceuticals Inc., a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company's lead product candidate is EP-104IAR, which is in a Phase II clinical trial for the treatment of unmet medical needs and for pain relief for knee osteoarthritis, as well as under development for treating canine and equine osteoarthritis. Its products in development also include EP-201, an antibiotic for post-surgical site infections; and EP-105, an extended-release post-surgical anesthetic for post-surgical pain. In addition, the company develops product candidates for oncology. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012.Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.
Past 5 years
StockViz Staff
February 6, 2025
Any question? Send us an email